The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
Prof. Kypros has revolutionised the field of fetal medicine through his extensive research and medical practice achievements, including introducing intrauterine blood transfusions for fetal anaemia
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
SAATH is a ‘One AXA’ public health initiative between AXA France Vie, AXA GO Business Operations, and AXA XL
It will be the first and only global office for traditional medicine in the world
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Subscribe To Our Newsletter & Stay Updated
